Overactive Bladder Therapeutics
1. Enablex patent expiration
Treatment: Treating urinary incontinence by administering an extended-release form of darifenacin; Treating a disease of altered motility or tone of smooth muscle by administering a muscarinic receptor antagoniz...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6106864 | ABBVIE | Pharmaceutical formulations containing darifenacin |
Aug, 2016
(9 years ago) | |
| US5096890 | ABBVIE | Pyrrolidine derivatives |
Mar, 2015
(10 years ago) | |
Drugs and Companies using DARIFENACIN HYDROBROMIDE ingredient
Market Authorisation Date: 22 December, 2004
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ENABLEX before it's drug patent expiration?
More Information on Dosage
ENABLEX family patents
2. Gemtesa patent expiration
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacol...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8247415 | SUMITOMO PHARMA AM | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2034
(8 years from now) | |
| US8653260 | SUMITOMO PHARMA AM | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
Apr, 2029
(3 years from now) | |
| US12180219 | SUMITOMO PHARMA AM | Process for preparing beta 3 agonists and intermediates |
Mar, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357636 | SUMITOMO PHARMA AM | NA |
May, 2042
(16 years from now) | |
| US12102638 | SUMITOMO PHARMA AM | Use of vibegron to treat overactive bladder |
Mar, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
| New Indication(I-955) | Dec 18, 2027 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Dosage: TABLET
More Information on Dosage
GEMTESA family patents
3. Myrbetriq patent
expiration
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency; For the treatment of
MYRBETRIQ's oppositions filed in EPO
MYRBETRIQ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6699503 | APGDI | Hydrogel-forming sustained-release preparation |
Sep, 2013
(12 years ago) | |
| US7750029 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec, 2023
(2 years ago) | |
| US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(2 years ago) | |
| USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(2 years ago) | |
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(3 years ago) | |
| US6562375 | APGDI | Stable pharmaceutical composition for oral use |
Aug, 2020
(5 years ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(2 years ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(2 years ago) | |
| US6346532 | APGDI | Amide derivatives or salts thereof |
Oct, 2018
(7 years ago) | |
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(2 years from now) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 8 months ago) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 8 months ago) | |
|
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 8 months ago) | |
|
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 8 months ago) | |
| US11707451 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(3 years from now) | |
| US12097189 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(3 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(3 years from now) | |
| US12059409 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(3 years from now) | |
|
US8772315 (Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(3 years from now) | |
|
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
|
US12097189 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
|
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
|
US12059409 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
| New Indication(I-777) | Apr 27, 2021 |
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage
MYRBETRIQ family patents
4. Toviaz patent expiration
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
TOVIAZ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(3 years ago) | |
| US7384980 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US7985772 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US7855230 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US8338478 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
|
US6858650 (Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(3 years ago) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
|
US7807715 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
|
US8088398 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
|
US8501723 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
| New Indication(I-861) | Jun 17, 2024 |
| Pediatric Exclusivity(PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TOVIAZ before it's drug patent expiration?
More Information on Dosage
TOVIAZ family patents
5. Vesicare patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6017927 | ASTELLAS | Quinuclidine derivatives and medicinal composition thereof |
Nov, 2018
(7 years ago) | |
|
US6017927 (Pediatric) | ASTELLAS | Quinuclidine derivatives and medicinal composition thereof |
May, 2019
(6 years ago) | |
Drugs and Companies using SOLIFENACIN SUCCINATE ingredient
Market Authorisation Date: 19 November, 2004
Dosage: TABLET
How can I launch a generic of VESICARE before it's drug patent expiration?
More Information on Dosage
VESICARE family patents